<DOC>
	<DOCNO>NCT01586572</DOCNO>
	<brief_summary>Globally , polio case decrease 99 % since 1988 . However , wild poliovirus case continue Pakistan . Conflict lack access child due on-going insecurity tribal area present special challenge interrupt transmission rapidly . There exist limited knowledge effect shorter interval mOPV vaccination immunogenicity level young child . The aim study demonstrate non-inferiority shorter interval ( 7 14 day ) dose mOPV1 vaccine compare customary interval ( 30 day ) . A 4th arm receive bivalent ( bOPV ) vaccine standard interval begin 6 week age .</brief_summary>
	<brief_title>Pakistan Short Interval mOPV1 Compared With Standard Interval mOPV1 bOPV 1,3</brief_title>
	<detailed_description>This randomize clinical trial conduct 5 low-income area around Karachi ( 4 peri-urban , contiguous coastal village outside Karachi , one urban squatter settlement ) Aga Khan University 's Department Paediatrics Child Health well-established demographic surveillance pregnancy new birth area capture system . The study participant enrol birth 102 day . Subjects randomize one four trial arm . All child receive tOPV birth . At 42 day ( 6 week ) age , three study arm receive dose mOPV1 whereas fourth arm receive dose bOPV1 &amp; 3 per protocol . Then 7 14 30 day later , study participant Arms A , B , C receive second dose mOPV1 second dose bOPV 1 &amp; 3 give participant Arm D 30 day . Name description product : 1 . Standard trivalent oral poliovirus vaccine ( tOPV ) , 10:1:6 formulation , contain least 106 TCID50 Sabin -strain poliovirus type 1 , least 105 TCID50 Sabin-strain poliovirus type 2 least 105.8 TCID50 Sabin-strain poliovirus type 3 . 2 . Monovalent type 1 oral poliovirus vaccine ( mOPV1 ) contain least106 TCID50 Sabin- strain poliovirus type 1 . 3 . The bivalent oral polio vaccine contain least 106 CCID50 Sabin poliovirus type 1 105â€¢8 CCID50 Sabin poliovirus type 3 . Sample Size : To show non-inferiority 2-dose mOPV1 schedule shorter-intervals ( either 7 14 day ) [ intervention ] compare 2-dose mOPV1 schedule administer 30-day interval [ control ] , 2-dose bOPV13 schedule administer 30-day interval ( control ) assume power 0.90 ( beta ) p 0.05 ( alpha ) , require sample 139 study group , total 556 subject . To compensate drop , attrition insufficient serum laboratory testing , inflate ( ~ 50 % ) sample size 200 group use ( total sample size 800 ) Efficacy Endpoints : The primary endpoint seroconversion antibody poliovirus type 1 follow two-dose schedule mOPV1 give interval 7 14 day compare mOPV1 bOPV1 &amp; 3 give standard interval 30 days.. The secondary endpoint seroconversion follow birth dose tOPV . All sample process Centers Disease Control Prevention CDC ) Laboratories ( Global Specialized Polio Network Laboratory ) .</detailed_description>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Infants &gt; 2.5 kg birth weight Immediate cry No neonatal IMCI danger sign Not plan travel away entire study period ( birth102 day ) Highrisk newborn exclude , well newborns require hospitalization Birth weight 2.5 kg Cry &gt; 2 minute With neonatal IMNCI danger sign Residence &gt; 30 km study site Family planning absent birth 102 day study period . A diagnosis suspicion immunodeficiency disorder ( either participant member immediate family e.g . several early infant death , household member chemotherapy ) render newborn ineligible study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Hours</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Polio virus type 1,2,3</keyword>
	<keyword>Poliovaccine-Oral</keyword>
	<keyword>Poliovaccine</keyword>
	<keyword>Trivalent Oral Polio vaccine</keyword>
	<keyword>Monovalent oral polio vaccine</keyword>
	<keyword>Bivalent Oral polio vaccine</keyword>
</DOC>